drugset / Trial / NCT06383533
Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
It is a single arm, open-label, phase II cinical trial to evaluate the efficacy and safety of Disitamab Vedotin Plus Cadonilimab in second-line treatment of patients with Advanced or Metastatic Bile Duct Adenocarcinoma
Timeline
- Start
- 2023-05-01
- Primary completion
- 2025-05-01
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 6 mg/kg | Other |
| Subject | Disitamab Vedotin | Monoclonal antibody | 2 mg/kg | Other |